Pictet Asset Management Holding SA Sells 33,122 Shares of Bruker Corporation $BRKR

Key Points

• Pictet Asset Management trimmed its Bruker stake by 22.3%, selling 33,122 shares in Q4 and leaving 115,121 shares (about $5.42M), while overall institutional ownership is roughly 79.5%.
• Bruker missed Q4 EPS ($0.59 vs. $0.65 expected) on $977.2M revenue, issued FY2026 guidance of 2.10–2.15 EPS (MarketBeat consensus ~2.12), and trades with a negative trailing P/E and a $5.6B market cap.
• Analyst sentiment is mixed — MarketBeat's consensus is a Hold with a $49.38 average target amid notable price-target cuts (e.g., Goldman to $35) — and insiders hold 27.2% of shares, with VP Mark Munch recently selling 2,000 shares at $39.90.

Pictet Asset Management Holding SA reduced its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 22.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 115,121 shares of the medical research company's stock after selling 33,122 shares during the period. Pictet Asset Management Holding SA owned about 0.08% of Bruker worth $5,423,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd bought a new stake in Bruker during the 2nd quarter worth approximately $192,735,000. AQR Capital Management LLC increased its holdings in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. UBS Group AG increased its holdings in Bruker by 196.4% during the 3rd quarter. UBS Group AG now owns 1,413,919 shares of the medical research company's stock worth $45,938,000 after purchasing an additional 936,820 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its holdings in Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock worth $67,909,000 after purchasing an additional 796,510 shares in the last quarter. Finally, Royal London Asset Management Ltd. bought a new stake in Bruker during the 2nd quarter worth approximately $32,478,000. 79.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company's stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 27.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. The Goldman Sachs Group decreased their price objective on Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a report on Friday, February 13th. TD Cowen raised Bruker to a "hold" rating in a report on Monday, April 13th. Guggenheim cut their target price on Bruker from $58.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Citigroup cut their target price on Bruker from $53.00 to $40.00 and set a "neutral" rating on the stock in a research note on Friday, February 13th. Finally, Weiss Ratings upgraded Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $49.38.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $36.79 on Monday. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The stock's 50 day moving average price is $37.13 and its 200-day moving average price is $41.97. The company has a market capitalization of $5.60 billion, a PE ratio of -245.27, a PEG ratio of 2.20 and a beta of 1.12. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business had revenue of $977.20 million during the quarter, compared to analysts' expectations of $964.61 million. During the same quarter in the previous year, the firm earned $0.76 EPS. Bruker's quarterly revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker's dividend payout ratio is -133.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.